Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration

Type 1 diabetes mellitus results from a cell-mediated autoimmune attack against pancreatic ß-cells. Traditional treatments involve numerous daily insulin dosages/injections and rigorous glucose control. Many efforts toward the identification of ß-cell precursors have been made not only with the aim of understanding the physiology of islet regeneration, but also as an alternative way to produce ß-cells to be used in protocols of islet transplantation. In this review, we summarize the most recent studies related to precursor cells implicated in the regeneration process. These include embryonic stem cells, pancreas-derived multipotent precursors, pancreatic ductal cells, hematopoietic stem cells, mesenchymal stem cells, hepatic oval cells, and mature ß-cells. There is controversial evidence of the potential of these cell sources to regenerate ß-cell mass in diabetic patients. However, clinical trials using embryonic stem cells, umbilical cord blood or adult bone marrow stem cells are under way. The results of various immunosuppressive regimens aiming at blocking autoimmunity against pancreatic ß-cells and promoting ß-cell preservation are also analyzed. Most of these regimens provide transient and partial effect on insulin requirements, but new regimens are beginning to be tested. Our own clinical trial combines a high dose immunosuppression with mobilized peripheral blood hematopoietic stem cell transplantation in early-onset type 1 diabetes mellitus.

Saved in:
Bibliographic Details
Main Authors: Couri,C.E.B., Foss,M.C., Voltarelli,J.C.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2006
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000002
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2006001000002
record_format ojs
spelling oai:scielo:S0100-879X20060010000022008-02-12Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regenerationCouri,C.E.B.Foss,M.C.Voltarelli,J.C. Diabetes mellitus ß-cell regeneration ß-cell preservation ß-cell precursors Immune intervention Stem cell Type 1 diabetes mellitus results from a cell-mediated autoimmune attack against pancreatic ß-cells. Traditional treatments involve numerous daily insulin dosages/injections and rigorous glucose control. Many efforts toward the identification of ß-cell precursors have been made not only with the aim of understanding the physiology of islet regeneration, but also as an alternative way to produce ß-cells to be used in protocols of islet transplantation. In this review, we summarize the most recent studies related to precursor cells implicated in the regeneration process. These include embryonic stem cells, pancreas-derived multipotent precursors, pancreatic ductal cells, hematopoietic stem cells, mesenchymal stem cells, hepatic oval cells, and mature ß-cells. There is controversial evidence of the potential of these cell sources to regenerate ß-cell mass in diabetic patients. However, clinical trials using embryonic stem cells, umbilical cord blood or adult bone marrow stem cells are under way. The results of various immunosuppressive regimens aiming at blocking autoimmunity against pancreatic ß-cells and promoting ß-cell preservation are also analyzed. Most of these regimens provide transient and partial effect on insulin requirements, but new regimens are beginning to be tested. Our own clinical trial combines a high dose immunosuppression with mobilized peripheral blood hematopoietic stem cell transplantation in early-onset type 1 diabetes mellitus.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.39 n.10 20062006-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000002en10.1590/S0100-879X2006005000010
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Couri,C.E.B.
Foss,M.C.
Voltarelli,J.C.
spellingShingle Couri,C.E.B.
Foss,M.C.
Voltarelli,J.C.
Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
author_facet Couri,C.E.B.
Foss,M.C.
Voltarelli,J.C.
author_sort Couri,C.E.B.
title Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
title_short Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
title_full Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
title_fullStr Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
title_full_unstemmed Secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
title_sort secondary prevention of type 1 diabetes mellitus: stopping immune destruction and promoting ß-cell regeneration
description Type 1 diabetes mellitus results from a cell-mediated autoimmune attack against pancreatic ß-cells. Traditional treatments involve numerous daily insulin dosages/injections and rigorous glucose control. Many efforts toward the identification of ß-cell precursors have been made not only with the aim of understanding the physiology of islet regeneration, but also as an alternative way to produce ß-cells to be used in protocols of islet transplantation. In this review, we summarize the most recent studies related to precursor cells implicated in the regeneration process. These include embryonic stem cells, pancreas-derived multipotent precursors, pancreatic ductal cells, hematopoietic stem cells, mesenchymal stem cells, hepatic oval cells, and mature ß-cells. There is controversial evidence of the potential of these cell sources to regenerate ß-cell mass in diabetic patients. However, clinical trials using embryonic stem cells, umbilical cord blood or adult bone marrow stem cells are under way. The results of various immunosuppressive regimens aiming at blocking autoimmunity against pancreatic ß-cells and promoting ß-cell preservation are also analyzed. Most of these regimens provide transient and partial effect on insulin requirements, but new regimens are beginning to be tested. Our own clinical trial combines a high dose immunosuppression with mobilized peripheral blood hematopoietic stem cell transplantation in early-onset type 1 diabetes mellitus.
publisher Associação Brasileira de Divulgação Científica
publishDate 2006
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000002
work_keys_str_mv AT couriceb secondarypreventionoftype1diabetesmellitusstoppingimmunedestructionandpromotingßcellregeneration
AT fossmc secondarypreventionoftype1diabetesmellitusstoppingimmunedestructionandpromotingßcellregeneration
AT voltarellijc secondarypreventionoftype1diabetesmellitusstoppingimmunedestructionandpromotingßcellregeneration
_version_ 1756391158644211712